EP0354948A1 - Hydrophiles, vernetztes copolymer zur medizinischen und paramedizinischen verwendung - Google Patents

Hydrophiles, vernetztes copolymer zur medizinischen und paramedizinischen verwendung

Info

Publication number
EP0354948A1
EP0354948A1 EP89902252A EP89902252A EP0354948A1 EP 0354948 A1 EP0354948 A1 EP 0354948A1 EP 89902252 A EP89902252 A EP 89902252A EP 89902252 A EP89902252 A EP 89902252A EP 0354948 A1 EP0354948 A1 EP 0354948A1
Authority
EP
European Patent Office
Prior art keywords
product according
copolymer
crosslinked
medical
hydrophilic copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89902252A
Other languages
English (en)
French (fr)
Inventor
Brigitte De Zaepffel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZAEPFFEL BRIGITTE
Original Assignee
ZAEPFFEL BRIGITTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZAEPFFEL BRIGITTE filed Critical ZAEPFFEL BRIGITTE
Publication of EP0354948A1 publication Critical patent/EP0354948A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a product for medical and paramedical use, it being understood that these terms must be taken in their broadest acceptations.
  • medical use we will also mean “veterinary use” and “surgical use”, while by “paramedical use”, we will also mean “care uses”, “dietetic uses”, as well as uses “as of survival ration ".
  • the product defined above consists essentially of a hydrophilic copolymer of the acrylamide / crosslinked alkaline acrylate or vinyl alcohol / crosslinked alkaline acrylate type and the invention will be described below with reference more particularly and respectively to the acrylamide copolymers and sodium acrylate, and vinyl alcohol and sodium acrylate, which are the preferred products.
  • Copolymers of crosslinked acrylamide and sodium acrylate are well known for their use in fields as diverse as in agriculture and in the adhesives and powders industry used in color reprography. It must be said that they have the property of gelling in aqueous media and of absorbing, depending on the particle size of the powders in the form of which they are present, several hundred times their own volume of water. All the big names in medical chemistry and others are associated with this kind of copolymers, for example Hoechst, Minesota Mining, Du Pont De Nemours, Eastman Kodak, Hitachi, Suminomo Chemical, Fuj i Photo, Ricoh, Toray Industries, Yasua. ..
  • the present invention relates to uses of such a product in a very different technical field, since it concerns the medical and paramedical fields in the broad sense indicated above. It has been found in fact that the copolymers have, vis-à-vis the human and animal organism, properties of "neutrality" which allow them this kind of applications.
  • the invention therefore relates to a product for medical and paramedical use, characterized in that it consists essentially of a crosslinked alkaline hydrophilic copolymer, of the following basic units:
  • R 1 , R 2 , R 3 , R ' 1 , R' 2 , R ' 3 which may be the same or different are hydrogen atoms or C 1 -C 3 alkyl groups
  • Me represents an alkali metal
  • Z represents OH or the CONH 2 group.
  • This product can be reduced to powder, advantageously having an average particle diameter of between 50 and 700 ⁇ m, preferably around 250 ⁇ m, in the dry state.
  • it gels in the presence of any aqueous (water, serum, etc.) or hydroalcoholic medium, absorbing between 500 and 700 times its volume. of water.
  • the gelation process is relatively quick, since it takes between 0.5 and 5 minutes to acquire maximum and final swelling in an aqueous medium. Soaked, the powder has an average particle diameter of between 450 and 6200 ⁇ m, preferably around 3000 ⁇ m.
  • This powder is completely harmless vis-à-vis higher beings, especially mammals and humans.
  • the product according to the invention preferably packaged in the form of capsules, can be absorbed orally and will swell in the stomach by filling it and cutting the feeling of hunger.
  • the product according to the invention is not absorbed by the organism and is therefore completely neutral with respect thereto.
  • the product according to the invention is ingested as it is, without other excipients than those necessary for the form of packaging or for the galenic form considered.
  • Another use consists in fixing on the product according to the invention, in calculated quantity, the nutrients (proteins, lipids, carbohydrates, vitamins, mineral salts, trace elements, etc.) necessary for the human organism, in order to constitute more appetizing survival rations than a concentrate or pills, while having the advantage, as above, of cutting the feeling of hunger dictated by the stomach.
  • the product according to the invention can be packaged, in an appropriate form, in a woven or nonwoven envelope according to the type of application and be used for its properties. of absorption as dressings and compresses, taking advantage of its very great ability to absorb liquids. In the same way, we can make mattress covers, or diapers for babies or adults with incontinence. It can also be packaged, in an appropriate form, as sanitary napkins or tampons where its absorbent properties will be highly appreciated. In the field of medical care, whether or not impregnated with an active principle having curative or healing properties and housed in an appropriate envelope, it can be used as a surgical compress or dry or wet plaster.
  • the product according to the invention can be impregnated with an active principle and be deposited on the surface of the organism or be transported inside it. Ingested orally, it can be used as a gastric dressing to protect the intestinal mucosa and to treat, calm pain in gatrites, esophagitis, gastrointestinal ulcers, colitis, polyposis, polyps, etc.
  • the product according to the invention impregnated with an active principle can be used for an internal topical application, the copolymers protecting the active principle from too rapid degradation and therefore making it possible to send it to the site where he must act.
  • the product according to the invention impregnated with an active principle can be applied locally, either by injection, or directly on the skin where the latter will act in the manner of a transdermal.
  • the product according to the invention constitutes an excellent maintenance or filling substance, inert with respect to the organism and in practice non-biodegradable. It will then be used by injection or by incision for the treatment of wrinkles for example, breast ptosis or as prosthesis or plasty, testicles, etc.
  • the stool was collected for five days. They were washed and sieved through a filter with a porosity of 500 m. The collected material was collected and weighed at the end of the observation period. The recovered weight is as follows for the five subjects:
  • the average recovery value is 26.88 g which, taking into account losses due to handling, represents an almost total elimination of the product.
  • the suspensions were incubated for four hours in an incubator at 37 ° C. After incubation, the cells were counted. The number of cells recovered is of the same order of magnitude as the entire initial sample (between 49,250 and 50015). Furthermore, the weight after centrifugation is the same as that observed at the start of the experiment.
  • copolymer particles swollen with water do not seem to be attacked by the enzymes used. This result confirms the results concerning elimination by the digestive tract.
  • the aim of this study is to determine the allergenic potential of the copolymer particles. To do this, a dose of twice 2.0 g / day, in the presence of water, is administered for 5 days to 20 volunteers.
  • the behavior of the immunocompetent and phagocytic cells with respect to the copolymer particles is analyzed. Insofar as some small particles could possibly cross the intestinal wall, it is useful to know their fate and their effects on immune functions.
  • swollen particles from 20,000 to 200,000 have been brought into contact with a constant population of lymphomonocytes from allergic patients. Incubation was carried out in RPMI medium in the presence of 10% of AB ° human serum. It was four hours. The cells were then placed 1 in the presence of Trypan blue and within 10 minutes of contacting, the number of viable cells was determined.
  • lymphomonocytes were practiced, the cells coming from allergic subjects.
  • mitogin PHA lectins, vegetable megin
  • Polynuclear cells from allergic patients isolated on Ficoll-Isopaque gradients were washed and in RPMI medium brought into contact with copolymer particles.
  • the cell / particle ratio was 1/5. Fifteen experiments were carried out.
  • the cell suspension was incubated for two hours at 37 ° C.
  • the separation of the cell / particle pair was made by sedimentation in a hypotonic aqueous medium.
  • 40 ⁇ 40 cm x 4 mm thick compresses are prepared by enclosing balls of the ⁇ IGETAGEL brand copolymer sold by OMAREX in a non-woven envelope, which, in turn, may in turn be covered with a gauze. traditional. These compresses are applied to wounds where their absorbent properties work wonders compared to traditional compresses. In addition, they are a remarkable barrier against infection of wounds by germs from the outside.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP89902252A 1988-02-12 1989-02-09 Hydrophiles, vernetztes copolymer zur medizinischen und paramedizinischen verwendung Withdrawn EP0354948A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH511/88 1988-02-12
CH51188 1988-02-12

Publications (1)

Publication Number Publication Date
EP0354948A1 true EP0354948A1 (de) 1990-02-21

Family

ID=4188685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89902252A Withdrawn EP0354948A1 (de) 1988-02-12 1989-02-09 Hydrophiles, vernetztes copolymer zur medizinischen und paramedizinischen verwendung

Country Status (4)

Country Link
EP (1) EP0354948A1 (de)
JP (1) JPH02503205A (de)
AU (1) AU3049489A (de)
WO (1) WO1989007455A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013566A1 (en) * 1991-01-31 1992-08-20 Massachusetts Institute Of Technology Interpenetrating-polymer network phase-transition gels
UA10911C2 (uk) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" Біосумісhий гідрогель
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
CA2318417A1 (en) * 1998-01-09 1999-07-15 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6660301B1 (en) 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
WO2001070289A2 (en) 2000-03-20 2001-09-27 Biosphere Medical, Inc. Injectable and swellable microspheres for tissue bulking
US7338657B2 (en) 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
US6436424B1 (en) 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
KR100872884B1 (ko) 2000-03-24 2008-12-10 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
MY130475A (en) 2000-08-25 2007-06-29 Contura As Polyacrylamide hydrogel and its use as an endoprosthesis
US7186419B2 (en) 2000-08-25 2007-03-06 Contura Sa Polyacrylamide hydrogel for arthritis
JP2002360222A (ja) * 2001-06-08 2002-12-17 Nissei Kosan Kk 肥満防止乃至予防食品
US7049345B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
KR101429774B1 (ko) 2005-05-09 2014-10-02 바이오스피어 메디칼 에스.에이. 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및방법
US9457048B2 (en) 2008-02-05 2016-10-04 Wellosophy Corporation Absorbent ingestible agents and associated methods of manufacture and use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1534771A (fr) * 1966-05-31 1968-08-02 Dow Chemical Co Copolymères faiblement réticulés, absorbant les fluides aqueux de façon stable et irréversible
FR2077687B1 (de) * 1970-02-05 1973-03-16 Roussel Uclaf
DE2935712A1 (de) * 1978-09-07 1980-03-20 Sumitomo Chemical Co Verfahren zum herstellen von stark absorbierenden polymerisaten
EP0206808A3 (de) * 1985-06-24 1987-08-19 American Colloid Company Kontinuverfahren zur Herstellung von Polyacrylat Harzen
EP0237267B1 (de) * 1986-03-11 1991-01-23 Barry Anthony Thompson Füttern von Vieh mit Polymeren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8907455A1 *

Also Published As

Publication number Publication date
WO1989007455A1 (fr) 1989-08-24
JPH02503205A (ja) 1990-10-04
AU3049489A (en) 1989-09-06

Similar Documents

Publication Publication Date Title
EP0354948A1 (de) Hydrophiles, vernetztes copolymer zur medizinischen und paramedizinischen verwendung
US10226476B2 (en) Method of attenuating reactions to skin irritants
Kumar et al. Psyllium mucilage and its use in pharmaceutical field: an overview
Ray Potential aspects of chitosan as pharmaceutical excipient
WO2007125533A2 (en) Orally administrable films and preparation thereof
JP2008037871A (ja) アトピー性皮膚炎治療用水和ゲル及びその製造方法
CA2538093A1 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
Yenilmez et al. Chitosan gel formulations containing egg yolk oil and epidermal growth factor for dermal burn treatment
US6660722B2 (en) Therapeutical treatments
Namdev et al. Floating Drug Delivery Systems: An emerging trend for the treatment of peptic ulcer
Wani et al. Chitosan and Aloe vera: Two gifts of nature
Jain et al. Gastroretentive metformin loaded nanoparticles for the effective management of type-2 diabetes mellitus
CN107847439A (zh) 用于舌下施用的吡喃葡萄糖基脂质a和过敏原制剂
AU2013316718A1 (en) Improved wound healing compositions comprising microspheres
JP2004229534A (ja) 加水分解卵殻膜含有飲料
WO2018234680A1 (fr) Composition auto-moussante en milieu acide et procédé de préparation
CA3145274A1 (fr) Souches bacteriennes de faecalibacterium prausnitzii et de christensenella pour le traitement et la prevention d'une inflammation gastro-intestinale
Chattopadhyay et al. Accentuated transdermal application of glucosamine sulphate attenuates experimental osteoarthritis induced by monosodium iodoacetate
WO2020104630A1 (fr) Traitement des affections de la peau à base d'eau électrolysée
CN111973636A (zh) 一种肛肠凝胶及其制备方法
Arenas Tropical dermatology
EP3087990B1 (de) Gelbildendes pulver enthaltend sulfamonomethoxin und chitosan zur behandlung von wunden
RU2291690C2 (ru) Фармацевтическая противогерпетическая композиция
ES2812148T3 (es) Preparación para el control del peso corporal a base de quitosano y celulosa
CN1196977A (zh) 超微食用粉的制作工艺

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920626

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920901